

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 34.61 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 25.39 | Oscillator | Neutral |
| Williams %R (14) | -81.40 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.50 (Hist 0.02) | Oscillator | Buy |
| Average Directional Index (14) | 42.73 (+DI 9.3 / -DI 28.0) | Trend | Strong Sell |
| EMA 20 | 13.40 | MA | Strong Sell |
| SMA 20 | 13.38 | MA | Strong Sell |
| EMA 50 | 14.50 | MA | Strong Sell |
| SMA 50 | 14.47 | MA | Strong Sell |
| SMA 200 | 18.43 | MA | Strong Sell |
Current price $12.81
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 20, 26 | Truist Securities | maintain | Buy | Buy |
| Oct 14, 26 | Mizuho | downgrade | Outperform | Neutral |
| Oct 5, 26 | UBS | maintain | Neutral | Neutral |
| Sep 30, 26 | Mizuho | maintain | Outperform | Outperform |
| Aug 13, 26 | JP Morgan | maintain | Neutral | Neutral |
| Aug 13, 26 | BMO Capital | maintain | Outperform | Outperform |
| Aug 10, 26 | UBS | downgrade | Buy | Neutral |
| Aug 6, 26 | RBC Capital | maintain | Outperform | Outperform |
| Aug 6, 26 | Truist Securities | maintain | Buy | Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 30, 26 | Mather Courtney | director | A-Award | 2,118 | — |
| Aug 12, 26 | Will David | officer: Chief Accounting Officer | F-InKind | 2,426 @ $15.24 | $36.97K |
| Aug 12, 26 | Familiar Calderon Gerardo | officer: See Remarks | P-Purchase | 1,935 @ $15.53 | $30.05K |
| Aug 11, 26 | Dignam Denise | director, officer: Chief Executive Officer | P-Purchase | 3,378 @ $14.95 | $50.50K |
| Aug 7, 26 | Cowan Alister | director | P-Purchase | 13,000 @ $15.62 | $203.1K |
| Aug 7, 26 | Foley Michael Robert | officer: See Remarks | P-Purchase | 1,934 @ $15.51 | $30.00K |
| Aug 7, 26 | Cranston Mary B | director | P-Purchase | 6,000 @ $15.83 | $94.95K |
| Aug 7, 26 | Martinko Joseph T. | officer: See Remarks | P-Purchase | 1,940 @ $15.47 | $30.01K |
TTM vs. 5-year historical average (annual ratios)
| Metric | CC | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -6.4x | 4.4x · sector 16.6x | Discount |
| Forward P/E (FY26E) | 13.5x | EPS est. 0.95 | Discount |
| Price / Book | -39.6x | 5.4x | Discount |
| Price / Sales | 0.3x | 0.6x | Discount |
| EV / EBITDA | -32.4x | 15.8x | Discount |
| Return on equity | -170.3% | — | Weak |
| Gross margin | 15.3% | 20.5% | Below hist. |
| Debt / Equity | -84.08 | 7.72 | Conservative |
| Piotroski / Altman Z | 5/9 | Z 1.17 | Distress |
Discounted cash flow model
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In The Chemours To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in The Chemours between February 20, 2026 and August 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - October 24, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against The Chemours Company ("The Chemours" or the "Company") (NYSE: CC) and reminds investors of the December 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Chemours has been sued for securities fraud after its stock plummeted 18.63% because Chemours allegedly misrepresented the strength of demand
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | 0.49 | 0.42 | Miss -14.1% | $1.59B |
| May 5, 2026 | -0.05 | 0.05 | Beat 200.0% | $1.38B |
| Feb 19, 2026 | 0.09 | 0.05 | Miss -43.6% | $1.33B |
| Nov 6, 2025 | 0.24 | 0.20 | Miss -16.7% | $1.50B |
| Aug 5, 2025 | 0.46 | 0.58 | Beat 26.1% | $1.61B |
| May 6, 2025 | 0.19 | 0.13 | Miss -31.6% | $1.37B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 1, 2026 | 2026-10-01 17:24:10 | View |
| 8-K | Sep 10, 2026 | 2026-09-10 06:47:20 | View |
| 8-K | Sep 9, 2026 | 2026-09-09 06:31:27 | View |
| 4 | Aug 13, 2026 | 2026-08-13 17:25:03 | View |
| 4 | Aug 13, 2026 | 2026-08-13 17:25:02 | View |
| 4 | Aug 13, 2026 | 2026-08-13 17:15:04 | View |
| 4 | Aug 11, 2026 | 2026-08-11 16:10:04 | View |
| 4 | Aug 11, 2026 | 2026-08-11 16:10:04 | View |
| 4 | Aug 11, 2026 | 2026-08-11 16:10:03 | View |
| 4 | Aug 11, 2026 | 2026-08-11 16:10:03 | View |
Proxy statement (DEF 14A) disclosures